Company intelligence / Profile preview
Tianjin Chase Sun Pharmaceutical
Tianjin, Tianjin, Chinachasesun.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tianjin Chase Sun Pharmaceutical is a diversified pharmaceutical company with commercialized products in China and internationally. Its portfolio includes modern traditional Chinese medicines such as Xuebijing Injection (approved for sepsis and COVID‑19), small molecules for various indications including oncology and respiratory disease, as well as ongoing clinical programs targeting PD-L1 (brain cancer) and other mechanisms. The company has GMP-certified manufacturing capabilities for APIs and finished dosage forms.
- Therapeutic areas
- NeurologyPulmonologyInfectious DiseasesOncologyImmunologyCardiovascular
- Modalities
- Small moleculeHerbal medicinePeptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Tianjin Chase Sun Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Chase Sun Pharmaceutical.